LifeMD Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +155.9% | +76.1% | +60.0% | +107.0% | +31.7% | +288.9% | +272.5% | -48.6% | +127.9% | +23.9% | -2.8% | |
| – | +241.1% | +76.1% | +60.0% | +27.0% | +71.2% | +351.8% | +261.9% | -74.8% | +276.7% | +14.4% | +6.4% | |
| – | +208.6% | -21.6% | -22.6% | +27.4% | +514.5% | +729.5% | +350.2% | -90.4% | +737.3% | +5.6% | +5.1% | |
| – | +208.6% | -21.6% | -22.6% | +27.4% | +514.5% | +729.5% | +350.2% | -90.4% | +737.3% | +5.6% | +5.1% | |
| – | +931.6% | +189.4% | -71.3% | -22.7% | -1.6% | +923.9% | -1.8% | +189.2% | +86.2% | +55.7% | +13.2% | |
| – | +48.9% | +162.5% | +341.2% | +44.6% | -7.1% | +33.1% | +27.9% | +129.1% | -25.5% | +1.4% | -0.9% | |
| – | – | – | – | – | – | +1,061.6% | +623.8% | -76.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -33.2% | +6.0% | +321.3% | +320.2% | +16.8% | +7.0% | -98.3% | |
| – | -15.0% | +330.5% | -44.3% | +180.3% | +154.7% | +210.9% | +69.5% | +36.8% | +60.5% | +44.6% | -38.2% | |
| – | -11.3% | +330.5% | -44.3% | +86.0% | +233.4% | +250.5% | +63.8% | +37.5% | +10.9% | +73.2% | -31.0% | |
| – | +267.6% | +106.4% | -18.8% | +47.7% | +229.3% | +7.0% | -23.1% | +429.6% | -73.8% | +861.9% | -92.8% | |
| – | +18.5% | +349.6% | -37.1% | +83.5% | +245.0% | +247.2% | -13.0% | +11.6% | +9.7% | +44.4% | -11.6% | |
| – | – | – | – | – | – | – | – | – | – | -44.9% | – | |
| – | – | -454.9% | – | +1.8% | -210.1% | – | +1,883.2% | -125.4% | – | -256.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.2% | +10.1% | +24.8% | +2.9% | +9.3% | +44.2% | +89.2% | +14.7% | +9.5% | +21.5% | +9.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.